Qpex Biopharma - About the company
Qpex Biopharma is an acquired company based in San Diego (United States), founded in 2018. It operates as a Developer of therapies for treating infectious diseases. Qpex Biopharma has raised $33M in funding from New Enterprise Associates. The company has 217 active competitors, including 78 funded and 40 that have exited. Its top competitors include companies like Spero Therapeutics, Locus Biosciences and LimmaTech Biologics.
Company Details
Qpex Biopharma is developing therapies for treating infectious diseases. They have developed their own beta-lactamase inhibitor technology. With the help of this technology, they are developing antibiotics (undisclosed anti-infective candidates) that can be used for treating drug-resistant and gram-negative infections.
- Website
- qpexbio.com
- Registered Address
- San Diego, California
Key Metrics
Founded Year
2018
Location
San Diego, United States
Stage
Acquired
Total Funding
$33M in 1 round
Latest Funding Round
Investors
Ranked
15th among 217 active competitors
Employee Count
36 as on Aug 31, 2026
Similar Companies
Exit Details
Acquired by Shionogi (Jun 25, 2023)
Legal entities associated with Qpex Biopharma
Qpex Biopharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Qpex Biopharma, Inc. CIN: 831913418 , United States, Active | Dec 26, 999 | - | 12 (As on Dec 31, 2022) | - |
Qpex Biopharma's acquisition details
Click here to take a look at Qpex Biopharma's acquisition in detail
Sign up to download Qpex Biopharma's company profile
Qpex Biopharma's funding and investors
Qpex Biopharma has raised a total funding of $33M over 1 round. Its latest funding round was a Series A round on Jul 31, 2019 for $*****. 4 investors participated in its latest round. Qpex Biopharma has 4 institutional investors.
Here is the list of recent funding rounds of Qpex Biopharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 31, 2019 | 4450776 | Series A | 7538149 | 3176482 | 2718356 | 1221453 |
Access funding benchmarks and valuations. Sign up today!View details of Qpex Biopharma's funding rounds and investors
Qpex Biopharma's founders and board of directors
Founder? Claim ProfileQpex Biopharma's employee count trend
Qpex Biopharma has 36 employees as of Aug 26. Here is Qpex Biopharma's employee count trend over the years:
Uncover Qpex Biopharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Qpex Biopharma's Competitors and alternates
Top competitors of Qpex Biopharma include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Here is the list of Top 10 competitors of Qpex Biopharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Spero Therapeutics 2013, Cambridge (United States), Public | Developer of therapeutics for drug-resistant bacterial infections | $115M | 69/100 | |
2nd | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 64/100 | |
3rd | LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired | Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques | $40M | 63/100 | |
4th | Paratek Pharma 1996, Boston (United States), Acquired | Developer of therapeutics for antimicrobial resistant infections | $96.5M | 61/100 | |
5th |  Everest Medicines 2017, New York City (United States), Public | Developer of drugs for the treatment of cancer | $313M | 61/100 | |
6th |  Bioversys 2008, Basel (Switzerland), Public | Developer of therapeutics for Antimicrobial Resistance | $62.5M | 61/100 | |
7th | MicuRx Pharmaceuticals 2007, Foster City (United States), Series E | Develops antibiotics against multidrug-resistant (MDR) superbug infections | $272M | 60/100 | |
8th |  Vedanta Biosciences 2010, Cambridge (United States), Series E | Developer of therapeutics to treat infectious diseases | $410M | 59/100 | |
9th | Developer of multi-targeted antibacterial compounds | $7.51M | 59/100 | ||
10th | Pattern Bioscience 2016, Austin (United States), Series C | Provider of multiple diagnostics platforms for infectious diseases | $105M | 57/100 | |
15th |  Qpex Biopharma 2018, San Diego (United States), Acquired | Developer of therapies for treating infectious diseases | $33M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Qpex Biopharma's competitors? Click here to see the top ones
Qpex Biopharma's Investments and acquisitions
Qpex Biopharma has made no investments or acquisitions yet.
Reports related to Qpex Biopharma
Here is the latest report on Qpex Biopharma's sector:
News related to Qpex Biopharma
Filter this listMedia has covered Qpex Biopharma for 1 event in last 1 year, It was about people movement.
•
•
•
•
Shionogi to acquire Qpex Biopharma for $140mPharmaceutical Technology•Jun 26, 2023•Shionogi, Qpex Biopharma, Cleary Gottlieb
•
•
•
•
ArrePath Appoints Michael Dudley, PharmD, Chairman, Board of DirectorsBusiness Wire•Mar 24, 2022•ArrePath, Qpex Biopharma
•
Qpex Biopharma Announces Progress on Three Clinical Stage Programs for Antibiotic-Resistant Pathogens and Corporate UpdateBusiness Wire•Jan 19, 2022•Qpex Biopharma
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Qpex Biopharma
Explore our recently published companies
- Halmblog Music - Accra based, 2022 founded, Unfunded company
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company
- eomii - Unfunded company
- HOLTWORK - Unfunded company
